New Molecular Targets and Therapeutic Strategies against Cancer

Weinberg R.A. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 1989; 49: 3713–21.

Bishop J.M. Molecular themes in oncogenesis. Cell 1991; 64: 235–48.

Weinberg R.A. Tumour suppressor genes. Science 1991; 254: 1138–46.

Ponder B.A.J. Molecular genetics of cancer. BMJ 1992; 304: 1234–6.

Barbacid M. Ras genes. Annu Rev Biochem 1987; 56: 799–827.

Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682–9.

Lemoine N.R. , Mayall E.S. , Wyllie F.S. , Williams E.D. , Goyns M. , Stringer B. , Wynford-Thomas D. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989; 4: 159–64.

Fearon E. , Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–67.

Rodenhuis S. , Slebos R.J.C. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res (Suppl) 1992; 52: 2665s–9s.

Hamilton S.R. Molecular genetic alterations as potential prognostic indicators in colorectal carcinoma. Cancer (Suppl) 1992; 69 6: 1589–91.

Slebos R.T. , Kiberlan R.E. , Paledio O. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323: 561–5.

Smit VTHBM , Boot A.J.M. , Smits A.M.M. , Fleuren G.J. , Cornelisse C.J. , Bos J.L. K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucl Acids Res 1988; 16: 7773–82.

McCormick F. ras GTPase activating protein: signal transmitter and signal terminator. Cell 1989; 56: 5–8.

Hall A. ras and GAP-Who's controlling whom? Cell 1990; 61: 921–3.

McCormick F. The world according to GAP. Oncogene 1990; 5: 1281–3.

Mukhopadhyay T. , Tainsky M. , Cavender A.C. , Roth J. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 1991; 51: 1744–8.

Gibbs J.B. ras C-terminal processing enzymes-new drug targets? Cell 1991; 65: 1–4.

McManaway M.E. , Neckers L.M. , Loke S.L. Tumour specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet 1990; 335: 808–11.

Melani C. , Rivoltini L. , Parmiani G. , Calabretta B. , Colombo M.P. Inhibition of proliferation by c-myb antisense oligonucleotides in colon adenocarcinoma cell lines that express c-myb. Cancer Res 1991; 51: 2897–901.

Chang E.H. , Miller P.S. , Cushman C. , Devadas K. Antisense inhibition of rasp 21 expression that is sensitive to a point mutation. Biochemistry 1991; 30(34): 8283–6.

Schulz S. , Nyce J.W. Inhibition of protein isoprenylation and p21ras membrane association by dehydro-epiandrosterone in human colonic adenocarcinoma cells in vitro. Cancer Res 1991; 51(24): 6563–7.

Tabler M. , Tsagris M. Catalytic antisense RNAs produced by incorporating ribozyme cassettes into cDNA. Gene 1991; 108(2): 175–83.

Bennett M.J. , Cullimore J.V. Selective cleavage of closely related mRNAs by synthetic ribozymes. Nucleic Acids Res 1992; 20(4): 831–7.

Perriman R. , Delves A. , Gerlach W.L. Extended target-site specificity for a hammerhead ribozyme. Gene 1992; 113(2): 157–63.

Hall A. Signal transduction through small GTPases- a tale of two GAPs. Cell 1992; 69(3): 389–91.

Helene C. Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides. Eur J Cancer 1991; 127(11): 1466–71.

Ng S. , Conlon J. , Lavecchio J. Production and characterization of monoclonal antibodies to Ha-ras and N-ras p 21. Hybridoma 1991; 10(4): 467–80.

Dedieu JF , Ronco J , Van-der-Werf S , Hogle JM , Menin Y. , Girard M. Poliovirus chimeras expressing sequences from the principal neutralization domain of human immunodeficiency virus type I. J Virol 1992; 66(5): 3161–7.

Di-Carlo A. , Mariano A. , Macchia P.E. , Moroni M.C. , Beguinot L. , Macchia V. Epidermal growth factor receptor in human brain tumors. J Endocrinol Invest 1992; 15(1): 31–7.

Berchuck A. , Rodriguez G.C. , Kamel A. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer: Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 1991; 164: 669.

Borg A. , Baldetrop B. , Ferno M. Erb-B2 amplification in breast cancer with a high rate of proliferation. Oncogene 1991; 6: 137–43.

Barnes D.M. , Bartkova J. , Camplejohn R.S. , Gullick W.J. , Smith P.J. , Millis R.R. Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer 1992; 28, 2/3: 644–8.

Gullick W.J. The role of EGFR and the c-erbB2 protein in breast cancer. Int J Cancer 1990; (Suppl 5): 55–61.

Berchuck A. , Kohler M.F. , Bast R.C. Oncogenes in ovarian cancer. Hemat/Oncol Clin N Amer 1992; 6, 4: 813–27.

Nishimura T. , Nakamura V. , Tsukamoto H. Human c-erbB2 protooncogene product as a target for bispecific-antibody-directed adoptive tumor immunotherapy. Int J Cancer 1992; 50(5): 800–4.

Nakagawa T. , Saitoh S. , Imoto S. Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia. Oncology 1992; 49(2): 114–22.

Lubbert M. , Mirro J. Jr. , Kitchingman G. , McCormick F. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia. Oncogene 1992; 7(2): 263–8.

Szczylik C. , Skorski T. , Nikolaides N.C. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 1991; 253: 562–8.

Chen W. , Peace D.J. , Rovira D.K. , You S.G. , Cheever M.A. T-cell immunity to the joining region of p210BCR-ABL protein. Proc Natl Acad Sci USA 1992; 89(4): 1468–72.

Ong G. , Sikora K. , Gullick W.J. Inactivation of the retinoblastoma gene does not lead to loss of TGF-beta receptors or response to TGF-beta in breast cancer cell lines. Oncogene 1991; 6(5): 761–3.

Goodrich D.W. , Chen Y. , Scully P. , Lee Wtt Expression of the retinoblastoma gene product in bladder carcinoma cells associates with a low frequency of tumor formation. Cancer Res 1992; 52(7): 1968–73.

Narod S.A. , Feunteun J. , Lynch H.T. , Watson P. , Conway T. , Lynch J. , Lenoir G.M. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet 1991; 338: 82–3.

Leone A. , McBride O.W. , Weston A. , Wang M.G. , Anglard P. , Cropp C.S. , Goepel J.R. , Lidereau R. , Callahan R. , Linehan W.M. Somatic allelic deletion of nm23 in human cancer. Cancer Res 1991; 51(9): 2490–3.

Goddard A.D. , Borrow J. , Freemont P.S. , Solomon E. Characterization of a zinc finger gene disrupted by the + (15;17) in acute promyelocytic leukemia. Science 1991; 254(5036): 1371–4.

Lane D.P. , Crawford L.V. T antigen is bound to a host protein in SV40 transformed cells. Nature 1979; 278: 261–3.

Stratton M.R. The p53 gene in human cancer. Eur J Cancer 1992; 28(1): 293–5.

Hollstein M. , Sidransky D. , Vogelstein B. , Harris C.C. p53 mutations in human cancers. Science 1991; 253: 49–53.

Barton C.M. , Staddon S.L. , Hughes C.M. , Hall P.A. , O'Sul-livan C. , Kloppel G. , Theis B. , Russell R.C. , Neoptolemos J. , Williamson R.C. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991; 64(6): 1076–82.

Santibanez-Koref M.F. , Birch J.M. , Hartley A.L. , Jones P.H. , Craft A.W. , Eden T. , Crowther D. , Kelsey A.M. , Harris M. p53 germline mutations in Li-Fraumeni syndrome. Lancet 1991; 338(8781): 1490–1.

Garber J.E. , Goldstein A.M. , Kantor A.F. , Dreyfus M.G. , Fraumeni J.F. Jr. , Li F.P. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 1991; 51(22): 6094–7.

Midgley C.A. , Fisher C.J. , Bartek J. , Vojtesek B. , Lane D. , Barnes D.M. Analysis of p53 expression in human tumours - an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci 1992; 101(Pt 1): 183–9.

Rosenberg S.A. , Aebersold P. , Cornetta P. Gene transfer into humans- immunotherapy using tumour infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323: 570–8.

Miller A.D. Human gene therapy comes of age. Nature 1992; 357(6378): 455–60.

Rosenberg S.A. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992; 10(2): 180–99.

Gutierrez A.A. , Lemoine N.R. , Sikora K. Gene therapy for cancer. Lancet 1992; 339: 715–21.

Sikora K. Gene therapy for cancer. Eur J Cancer 1991; 27(9): 1069–70.

Mutant Oncogenes. Targets for therapy ed. N. Lemoine and A. A. Epenetos 1992 publ. Chapman and Hall.